Search Results - "Horvath, L.G"

158 Overcoming Docetaxel Resistance in Prostate Cancer by Targeting FAK Phosphorylation, and Its Mode of Action by Lee, B.Y, Hochgräfe, F, Lin, H.M, Castillo, L, Raftery, M, Horvath, L.G, Daly, R.J

Get full text

The evolution of chemotherapy for the treatment of prostate cancer by Quinn, D.I., Sandler, H.M., Horvath, L.G., Goldkorn, A., Eastham, J.A.

“…Chemotherapy has been explored as a treatment option for metastatic prostate cancer since the early 1980s. Docetaxel, a taxane chemotherapeutic, was approved…”
Get full text

1409P Development of a clinically accessible, circulating prognostic lipid biomarker panel in men with mCRPC to guide potential metabolic intervention by Scheinberg, T., Fitzpatrick, M., Lin, H-M., Azad, A.A., Bonnitcha, P., Davies, A.G., Heller, G., Huynh, K., Mak, B., Mahon, K., Meikle, P., Sullivan, D., Horvath, L.G.

Get full text

1831P Dissecting the meaning of obesity in metastatic castration resistant prostate cancer: Size or metabolism? by Horvath, L.G., Kench, C., Mellor, R., Lin, H-M., Mak, B., Scheinberg, T., Mahon, K., Graham, L., Azad, A.A., Joshua, A.M., Stockler, M.R., Marx, G.M., Briscoe, K., Samaras, K.

Get full text

1792P Effects of enzalutamide on overall survival +/- early docetaxel in participants aged less than 70 yrs versus greater than or equal to 70 yrs in ENZAMET (ANZUP 1304) by Horvath, L.G., Davis, I.D., Martin, A., Zielinski, R., Thomson, A., Tan, T.H., Sandhu, S.K., Reaume, M.N., Pook, D., Parnis, F., North, S., Marx, G.M., McCaffrey, J.A., McDermott, R.S., Lawrence, N., Frydenberg, M., Chowdhury, S., Chi, K.N.N., Stockler, M.R., Sweeney, C.

Get full text

586P Minimal residual disease (MRD) detection using a tumour naïve circulating tumour DNA (ctDNA) assay in patients (pts) with resected colorectal cancer (CRC) in the phase III ASCOLT trial by Day, D., Starus, A., Gebski, V., Simes, J., Hayes, T., Padinharakam, S., Strickland, A.H., Briscoe, K., Varma, S., Barnet, M., Jackson, C., Horvath, L.G., Price, T.J., Tebbutt, N., Karki, B., Diakos, C.I., Chia, J., Toh, H.C., Jones, F.S., Segelov, E.

Get full text

Statins – No more cream for cancer by Gillessen, S., Horvath, L.G.

Get full text

318MO Circulating tumour DNA (ctDNA) dynamics, CEA and sites of recurrence for the randomised DYNAMIC study: Adjuvant chemotherapy (ACT) guided by ctDNA analysis in stage II colon cancer (CC) by Tie, J., Cohen, J., Lahouel, K., Lo, S.N., Wang, Y., Wong, R., Shapiro, J., Harris, S., Khattak, A., Burge, M., Horvath, L.G., Karapetis, C.S., Shannon, J., Singh, M., Yip, D., Papadopoulos, N., Tomasetti, C., Kinzler, K., Vogelstein, B., Gibbs, P.

Get full text

1713P Single-cell transcriptomic analysis of appendiceal cancer peritoneal disease by Strach, M.C., Yeung, N., Apostolov, E., Lin, H-M., Nagaraju, R.T., Ansari, N., Koh, C., Shin, J-S., Kench, J., Aziz, O., Swarbrick, A., Horvath, L.G., Barriuso, J., Mahon, K.

Get full text

264P Interim results from a phase I study of AMG 509 (xaluritamig), a STEAP1 x CD3 XmAb 2+1 immune therapy in patients with metastatic castration-resistant prostate cancer (mCRPC) by Kelly, W.K., Danila, D.C., Lin, C-C., Lee, J-L., Matsubara, N., Ward, P.J., Armstrong, A.J., Pook, D.W., Kim, M., Dorff, T., Fischer, S., Lin, Y-C., Horvath, L.G., Sumey, C., Yang, Z., Jurida, G., Connarn, J., Penny, H., Stieglmaier, J., Appleman, L.J.

Get full text

1765O Interim results from a phase I study of AMG 509 (xaluritamig), a STEAP1 x CD3 XmAb 2+1 immune therapy, in patients with metastatic castration-resistant prostate cancer (mCRPC) by Kelly, W., Danila, D., Lin, C-C., Lee, J-L., Matsubara, N., Ward, P., Armstrong, A.J., Pook, D., Kim, M., Dorff, T., Fischer, S., Lin, Y-C., Horvath, L.G., Sumey, C., Yang, Z., Jurida, G., Connarn, J., Penny, H., Stieglmaier, J., Appleman, L.J.

Get full text

635P Association of ceramide metabolism with resistance to androgen receptor signalling inhibitors in metastatic prostate cancer by Lin, H-M., Mak, B., Huynh, K., Kwan, E.M., Fettke, H., Tran, B., Davis, I.D., Mahon, K.L., Stockler, M.R., Briscoe, K., Marx, G.M., Du, P., Yu, J., Jia, S., Joshua, A.M., Azad, A.A., Butler, L.M., Meikle, P.J., Horvath, L.G.

Get full text

577O PRINCE: Interim analysis of the phase Ib study of 177Lu-PSMA-617 in combination with pembrolizumab for metastatic castration resistant prostate cancer (mCRPC) by Sandhu, S.K., Joshua, A.M., Emmett, L., Spain, L., Horvath, L.G., Crumbaker, M., Anton, A., Wallace, R., Pasam, A., Bressel, M., Cassidy, E., Banks, P., Kumar, A.R., Alipour, R., Akhurst, T., Kong, G., Davis, I.D., Williams, S., Hicks, R., Hofman, M.

Get full text

596P Impact of combined lipidomic and genetic aberrations on clinical outcomes in metastatic castration-resistant prostate cancer (mCRPC) by Mak, B., Lin, H-M., Kwan, E.M., Fettke, H., Tran, B., Davis, I.D., Mahon, K.L., Stockler, M.R., Briscoe, K., Marx, G.M., Kohli, M., Tan, W., Huynh, K., Du, P., Yu, J., Jia, S., Joshua, A.M., Azad, A.A., Meikle, P.J., Horvath, L.G.

Get full text

Epigenetic-induced repression of microRNA-205 is associated with MED1 activation and a poorer prognosis in localized prostate cancer by Hulf, T, Sibbritt, T, Wiklund, E D, Patterson, K, Song, J Z, Stirzaker, C, Qu, W, Nair, S, Horvath, L G, Armstrong, N J, Kench, J G, Sutherland, R L, Clark, S J

“…Deregulation of microRNA (miRNA) expression can have a critical role in carcinogenesis. Here we show in prostate cancer that miRNA-205 (miR-205) transcription…”
Get full text

LBA53 - Health-related quality of life (HRQL) in a randomized phase III trial of enzalutamide with standard first-line therapy for metastatic, hormone-sensitive prostate cancer (mHSPC): ENZAMET (ANZUP 1304), an ANZUP-led, international, co-operative group trial by Stockler, M.R., Martin, A.J., Dhillon, H., Davis, I.D., Chi, K.N., Chowdhury, S., Horvath, L.G., Lawrence, N.J., Marx, G.M., Caffrey, J Mc, McDermott, R., North, S.A., Parnis, F., Pook, D.W., Reaume, M.N., Sandhu, S.K., Tan, T.H., Thomson, A., Zielinski, R., Sweeney, C.J.

“…We previously reported that treatment with enzalutamide (ENZA) rather than an older non-steroidal anti-androgen (NSAA: bicalutamide, nilutamide, or flutamide),…”
Get full text

Health-related quality of life (HRQL) in a randomized phase III trial of enzalutamide with standard first-line therapy for metastatic, hormone-sensitive prostate cancer (mHSPC): ENZAMET (ANZUP 1304), an ANZUP-led, international, co-operative group trial by Stockler, M.R., Martin, A.J., Dhillon, H., Davis, I.D., Chi, K.N., Chowdhury, S., Horvath, L.G., Lawrence, N.J., Marx, G.M., Caffrey, J Mc, McDermott, R., North, S.A., Parnis, F., Pook, D.W., Reaume, M.N., Sandhu, S.K., Tan, T.H., Thomson, A., Zielinski, R., Sweeney, C.J.

Get full text

A prospective multicentre phase III validation study of AZGP1 as a biomarker in localized prostate cancer by Zhang, A.Y., Grogan, J.S., Mahon, K.L., Rasiah, K., Sved, P., Eisinger, D.R., Boulas, J., Vasilaris, A., Henshall, S.M., Stricker, P.D., Kench, J.G., Horvath, L.G.

“…Prostate cancers (PCs) with similar characteristics at the time of diagnosis can have very different disease outcomes. Conventional biomarkers of PC still lack…”
Get full text

390 POSTER Secreted frizzled-related protein 4 inhibits proliferation and metastatic potential in prostate cancer by Horvath, L.G., Lelliott, J.E., Kench, J.G., Lee, C.S., Grygiel, J.J., Henshall, S.M., Sutherland, R.L.

Get full text